---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-031309"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:34:26.770302+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL

## Summary
- Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).
- Cash $17M at Dec 31, 2025; expected to fund ops through Q4 2026 without new grants.
- Phase 1 APOLLO data: 66% objective response rate in relapsed NHL, 50% complete responses.
- MT-601 pancreatic cancer program to initiate in Q2 2026; Nature Medicine publication Jan 2026.
- New board member Kathryn Penkus Corzo appointed Nov 2025; Cellipont manufacturing collaboration.

## SEC filing metadata
- accession: 0001104659-26-031309
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/0001104659-26-031309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-031309
- JSON: https://secwatch.observer/filing/0001104659-26-031309.json
- Plain text: https://secwatch.observer/filing/0001104659-26-031309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.